CBS 2019
CBSMD教育中心
中 文

Congestive Heart Failure

Abstract

Recommended Article

Heart failure with preserved ejection fraction: from mechanisms to therapies Mechanical circulatory support devices in advanced heart failure: 2020 and beyond Stage B heart failure: management of asymptomatic left ventricular systolic dysfunction Fluid Volume Overload and Congestion in Heart Failure: Time to Reconsider Pathophysiology and How Volume Is Assessed Noninvasive Imaging for the Evaluation of Diastolic Function: Promises Fulfilled Circulating sST2 and catestatin levels in patients with acute worsening of heart failure: a report from the CATSTAT-HF study Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial 2019 ACC Expert Consensus Decision Pathway on Risk Assessment, Management, and Clinical Trajectory of Patients Hospitalized With Heart Failure: A Report of the American College of Cardiology Solution Set Oversight Committee

Review ArticleVolume 76, Issue 6, August 2020

JOURNAL:J Am Coll Cardiol. Article Link

Heart Failure With Recovered Left Ventricular Ejection Fraction: JACC Scientific Expert Panel

JE Wilcox, JC Fang, KB Margulies et al. Keywords: heart failure with recovered ejection fraction; myocardial recovery

ABSTRACT

Reverse left ventricular (LV) remodeling and recovery of LV function are associated with improved clinical outcomes in patients with heart failure with reduced ejection fraction. A growing body of evidence suggests that even among patients who experience a complete normalization of LV ejection fraction, a significant proportion will develop recurrent LV dysfunction accompanied by recurrent heart failure events. This has led to intense interest in understanding how to manage patients with heart failure with recovered ejection fraction (HFrecEF). Because of the lack of a standard definition for HFrecEF, and the paucity of clinical data with respect to the natural history of HFrecEF patients, there are no current guidelines on how these patients should be followed up and managed. Accordingly, thisJACCScientific Expert Panel reviews the biology of reverse LV remodeling and the clinical course of patients with HFrecEF, as well as provides guidelines for defining, diagnosing, and managing patients with HFrecEF.